Ocugen
12
1
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
2 terminated/withdrawn out of 12 trials
50.0%
-36.6% vs industry average
25%
3 trials in Phase 3/4
200%
4 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Role: lead
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Role: lead
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Role: lead
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Role: lead
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Role: lead
Expanded Access Program for RP in Adults
Role: lead
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
Role: lead
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
Role: lead
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
Role: lead
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
Role: lead
Dry Eye Disease Study With Brimonidine
Role: lead
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
Role: collaborator
All 12 trials loaded